Drug management of Parkinson's disease.
Levodopa remains the cornerstone for managing Parkinson's disease. Physician's preference usually determines the dopamine agonist chosen for the early phases of treatment. The concept of neuro-protection, however, remains unproven. A better understanding of the cause of the disease and treatment-related complications could make managing Parkinson's disease more rewarding.
Kishore
A
A
Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, BC.
Snow
B J
BJ
D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000145:classification / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology; D012642:Selegiline / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000627:therapeutic use
D000978:Antiparkinson Agents; D012642:Selegiline; D001971:Bromocriptine; D007980:Levodopa; D014282:Trihexyphenidyl; D000547:Amantadine